Obermatt
See Similar Stocks →

CRISIL

NSI:CRISIL · INE007A01025
Capital MarketsMedium

360° View

61
Price/Sales61
Price/Earnings1
Price/Book25
Dividend Yield99
Revenue Growth49
Profit Growth96
Capital Growth37
TSR 52w14
Leverage61
Liquidity100
Refinancing1
Combined79
Analyst Opinions5
Pro Holdings17
Opinion Changes50
Market Pulse60

Profile

CountryUSA
IndustryCapital Markets
SizeMedium
TypePublic Company
ExchangeNSEI
Founded1987
Employees6,127
Websitecrisil.com
ISININE007A01025
Last UpdateApr 2, 2026
Index & Theme
Online Analysis and ReferenceMachine LearningPredictive AnalyticsCustomer AnalyticsFinanceFinancial Services

Description

CRISIL Limited (CRISIL) is a global analytical company providing ratings, research, risk, and policy advisory services. As part of S&P Global, CRISIL impacts financial markets and businesses through its offerings that include comprehensive analytics…

Analysis

CRISIL's 360° View rank of 61 places it above its peer average — better than 61% of its true peers.

It's growing solidly (53) and reasonably valued (74). On safety it is financially sound (62), and the market shows skeptical sentiment (21). Taken together, its Combined rank of 79 reads as among the strongest overall.

360° rank · history

1007550250
61
2023202420252026

All-time high

85

Mar 2026

All-time low

11

Jan 2024

Average rank

48

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
61
13
16
20
Price/Earnings
1
11
9
15
Price/Book
25
4
2
5
Dividend Yield
99
1
59
55
Value (overall)
74
1
21
23

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare CRISIL with its peers
Kalaris Therapeutics
NMQ:KLRS
36
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zymeworks
NSQ:ZYME
43
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zura Bio
NAQ:ZURA
56
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zentalis Pharmaceuticals
NMQ:ZNTL
12
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Xoma Royalty
NMQ:XOMA
40
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →